Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of KarXT adjunctive to lithium, valproate, or lamotrigine for acute mania in bipolar I disorder
CTR20261630Phase 3Active
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of xanomeline in bipolar I disorder, sponsored by Bristol Myers Squibb. Started Apr 2026; status: active.
02
Drugs
xanomeline
03
Conditions
bipolar I disorder
Beyond the preview
Go deeper on CTR20261630.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261630.